2-甲基-3H-噻吩并[3,2-e]苯并咪唑 | 21788-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-甲基-3H-噻吩并[3,2-e]苯并咪唑
• 英文名称: 1-R-2-Methylthieno-<2,3-h>imidazol
• 英文别名: 2-methyl-3H-thieno[3,2-e]benzimidazole
• CAS: 21788-18-1
• 化学式: C₁₀H₈N₂S
• mdl: MFCD00807872
• 分子量: 188.253
• InChiKey: MVHXTTHWQRRVCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  56.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

文献信息

• BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20160176892A1

  公开（公告）日：2016-06-23

  The present invention relates to benzimidazole derivatives and their pharmaceutical compositions and uses, specifically to benzimidazole derivatives of Formula (I), or their stereoisomer, pharmaceutically acceptable salt or solvates thereof, in which R 1 , R 2 , R 3 , R 4 , R 5 and n have the definitions in the description; the present invention further relates to a pharmaceutical composition containing the compounds, methods for preparing the compounds, and use of the compounds for manufacturing of a medicament for prophylaxis and/or treatment of peptic ulcer, ulcer hemorrhage and diseases associated with gastric acid.

  本发明涉及苯并咪唑衍生物及其制药组合物和用途，具体涉及公式（I）的苯并咪唑衍生物或其立体异构体，其药学上可接受的盐或溶剂，其中R1、R2、R3、R4、R5和n在说明中有定义；本发明还涉及含有该化合物的制药组合物，制备该化合物的方法，以及将该化合物用于制造预防和/或治疗消化性溃疡、溃疡出血和与胃酸有关的疾病的药物的用途。
• BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：EP2532665B1

  公开（公告）日：2016-09-07
• US9315513B2
  申请人：——

  公开号：US9315513B2

  公开（公告）日：2016-04-19
• [EN] BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：KBP BIOSCIENCES CO LTD

  公开号：WO2011095057A1

  公开（公告）日：2011-08-11

  Benzimidazole derivatives and pharmaceutical compositions and use thereof are disclosed. Benzimidazole derivatives represented by general formula (I) or their stereoisomers, pharmaceutically acceptable compositions and solvates thereof are specifically disclosed, in which R1, R2, R3, R4, R5 and n are defined as in the description. Pharmaceutical compositions containing these compounds, the preparation methods for these compounds and uses of these compounds in the preparation of medicaments for preventing and/or treating peptic ulcer, ulcerous hemorrhage and the diseases relevant to gastric acid are also disclosed.